References
1. Hall GW. Childhood myeloid leukaemias. Best pract Res Clin Haematology. 2001;14(3):573-591.
2. Rubnitz JE. Current Management of Childhood Acute Myeloid Leukemia.Paediatr Drugs. 2017;19(1):1-10.
3. Zwaan CM, Kolb EA, Reinhardt D, et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. J Clin Oncol.2015;33(27):2949-2962.
4. Faulk K, Gore L, Cooper T. Overview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Paediatr Drugs. 2014;16(3):213-227.
5. Rubnitz JE, Inaba H. Childhood acute myeloid leukaemia. Br J Haematol. 2012;159(3):259-276.
6. Dutcher JP, Schiffer CA, Wiernik PH. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol. 1987;5(9):1364-1372.
7. Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia.Leuk Lymphoma. 2006;47(7):1245-1252.
8. Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246-3252.
9. Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children’s Oncology Group.Haematologica. 2012;97(11):1770-1773.
10. Oliveira LC, Romano LG, Prado-Junior BP, Covas DT, Rego EM, De Santis GC. Outcome of acute myeloid leukemia patients with hyperleukocytosis in Brazil. Med Oncol. 2010;27(4):1254-1259.
11. Tien FM, Hou HA, Tsai CH, et al. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients. Eur J Haematol.2018;101(1):86-94.
12. Canaani J, Labopin M, Socie G, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT. Am J hematol.2017;92(7):653-659.
13. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med.1985;103(4):620-625.
14. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-447.
15. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol.2009;27(24):4007-4013.
16. Liu LP, Zhang AL, Ruan M, et al. Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia. Cancer Med.2020;9(11):3647-3655.
17. Odom LF, Lampkin BC, Tannous R, Buckley JD, Hammond GD. Acute monoblastic leukemia: a unique subtype–a review from the Childrens Cancer Study Group. Leuk Res. 1990;14(1):1-10.
18. Tobelem G, Jacquillat C, Chastang C, et al. Acute monoblastic leukemia: a clinical and biologic study of 74 cases. Blood.1980;55(1):71-76.
19. Inaba H, Fan Y, Pounds S, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer.2008;113(3):522-529.
20. Andrade FG, Noronha EP, Brisson GD, et al. Molecular Characterization of Pediatric Acute Myeloid Leukemia: Results of a Multicentric Study in Brazil. Arch Medi Res. 2016;47(8):656-667.
21. Shaffer DW, Burris HA, O’Rourke TJ. Testicular relapse in adult acute myelogenous leukemia. Cancer. 1992;70(6):1541-1544.
22. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties. Blood. 1998;92(7):2322-2333.
23. Duployez N, Marceau-Renaut A, Boissel N, et al. Comprehensive mutational profiling of core binding factor acute myeloid leukemia.Blood. 2016;127(20):2451-2459.
24. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22(18):3741-3750.
25. Liang DC, Shih LY, Hung IJ, et al. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia.Cancer. 2002;94(12):3292-3298.
26. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia.1998;12(9):1333-1337.
27. Rombouts WJ, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia.2000;14(4):675-683.
28. Meshinchi S, Woods WG, Stirewalt DL, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood. 2001;97(1):89-94.
29. Best-Aguilera C, Rodrigo Gómez-Vázquez O, Elizabeth Guzmán-Hernández A, Monserrat Rojas-Sotelo R. Treatment of Acute Myeloid Leukemia with the FLT3 Gene Mutation. Curr Oncol Rep. 2017;19(3):21.
Figure 1 . Kaplan–Meier analyses for PFS and OS rates of AML patients. Patients with hyperleukocytosis had a lower 10-year PFS and OS rates than those without hyperleukocytosis (P =.041 and P =.051; 1A, 1B). There was a similar 10-year PFS and OS rates between patients in the WBC count 50-100×109/L and WBC count ≥100×109/L subgroups (P =.507 and P =.907; 1C, 1D).